[Effect of macrolide antibiotics on MUC5AC production in human bronchial epithelial cells].
Takeyama
K
K
Tamaoki
A
A
Kondo
M
M
Aoshiba
K
K
Nakata
J
J
Isono
K
K
Nagai
A
A
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D001980:Bronchi / Q000166:cytology* / Q000378:metabolism; D002478:Cells, Cultured; D017291:Clarithromycin / Q000494:pharmacology; D003864:Depression, Chemical; D004305:Dose-Response Relationship, Drug; D004847:Epithelial Cells / Q000378:metabolism*; D004917:Erythromycin / Q000494:pharmacology; D006801:Humans; D020672:I-kappa B Proteins / Q000378:metabolism; D008070:Lipopolysaccharides / Q000037:antagonists & inhibitors; D048052:Mitogen-Activated Protein Kinase 3; D020928:Mitogen-Activated Protein Kinases / Q000378:metabolism; D055271:Mucin 5AC; D009077:Mucins / Q000096:biosynthesis*; D000072000:NF-KappaB Inhibitor alpha; D010766:Phosphorylation / Q000187:drug effects; D016211:Transforming Growth Factor alpha / Q000037:antagonists & inhibitors
D000900:Anti-Bacterial Agents; D020672:I-kappa B Proteins; D008070:Lipopolysaccharides; C524678:MUC5AC protein, human; D055271:Mucin 5AC; D009077:Mucins; C000606204:NFKBIA protein, human; D016211:Transforming Growth Factor alpha; D000072000:NF-KappaB Inhibitor alpha; D004917:Erythromycin; D048052:Mitogen-Activated Protein Kinase 3; D020928:Mitogen-Activated Protein Kinases; D017291:Clarithromycin